New Challenges for Hypertension Treatment

被引:10
作者
Rosas-Peralta, Martin [1 ]
Marcela Jimenez-Genchi, Gladys [2 ]
机构
[1] Inst Mexicano Seguro Social, Ctr Med Nacl Siglo 21, Programa A Todo Corazon Codigo Infarto, Jefe Area Med, Mexico City, DF, Mexico
[2] Inst Mexicano Seguro Social, Ctr Med Nacl Siglo 21, Programa A Todo Corazon, Mexico City, DF, Mexico
关键词
Hypertension; Guidelines; Therapy; Mexico; ASSOCIATION TASK-FORCE; CLINICAL-PRACTICE GUIDELINES; SYSTOLIC BLOOD-PRESSURE; AMERICAN-COLLEGE; CARDIOVASCULAR RISK; GLOBAL BURDEN; TRIAL; METAANALYSIS; PREVENTION; MANAGEMENT;
D O I
10.1016/j.arcmed.2018.11.005
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
In Mexico around 22.3 million adult Mexicans have hypertension. An estimated 65 million adult Americans, or nearly one in four of the adult population of the United States, have hypertension. However, with the new classification from 2017 ACC/AHA guidelines which considered >= 130/80 mmHg as the new cutoff point to diagnosis of hypertension, the number of patients is at least twice, in other words around 40 million adult Mexicans potentially have hypertension. Although this new classification is directed to be more efficient in the changes of life style and nondrug strategies to stage one hypertension the real word evidence suggest that we need to be more careful in the selection of patients to be introduced in a drug therapy strategy. Elevations in systemic arterial pressures have been associated with increased cardiovascular morbidity and mortality including cardiovascular death, myocardial infarction, heart failure and stroke. It remains one of the most reversible causes of various disease states. This article aims to review current blood pressure (BP) targets and medical therapies for hypertension in the modern era, recognizing varying clinical characteristics such as comorbidities and patient risk profile. (C) 2018 IMSS. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:548 / 557
页数:10
相关论文
共 35 条
[1]  
[Anonymous], JAMA, DOI DOI 10.1001/JAMA.289.19.2560
[2]   Beta-blockers for primary prevention of heart failure in patients with hypertension - Insights from a meta-analysis [J].
Bangalore, Sripal ;
Wild, David ;
Parkar, Sanobar ;
Kukin, Marrick ;
Messerli, Franz H. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (13) :1062-1072
[3]   Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta-Analysis of Randomized Trials [J].
Bangalore, Sripal ;
Toklu, Bora ;
Gianos, Eugenia ;
Schwartzbard, Arthur ;
Weintraub, Howard ;
Ogedegbe, Gbenga ;
Messerli, Franz H. .
AMERICAN JOURNAL OF MEDICINE, 2017, 130 (06) :707-U382
[4]   Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension [J].
Berra, Elena ;
Azizi, Michel ;
Capron, Arnaud ;
Hoieggen, Aud ;
Rabbia, Franco ;
Kjeldsen, Sverre E. ;
Staessen, Jan A. ;
Wallemacq, Pierre ;
Persu, Alexandre .
HYPERTENSION, 2016, 68 (02) :297-+
[5]   Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial [J].
Bress, Adam P. ;
King, Jordan B. ;
Kreider, Kathryn E. ;
Beddhu, Srinivasan ;
Simmons, Debra L. ;
Cheung, Alfred K. ;
Zhang, Yingying ;
Doumas, Michael ;
Nord, John ;
Sweeney, Mary Ellen ;
Taylor, Addison A. ;
Herring, Charles ;
Kostis, William J. ;
Powell, James ;
Rastogi, Anjay ;
Roumie, Christianne L. ;
Wiggers, Alan ;
Williams, Jonathan S. ;
Yunis, Reem ;
Zias, Athena ;
Evans, Greg W. ;
Greene, Tom ;
Rocco, Michael V. ;
Cushman, William C. ;
Reboussin, David M. ;
Feinglos, Mark N. ;
Papademetriou, Vasilios .
DIABETES CARE, 2017, 40 (10) :1401-1408
[6]   Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality A Systematic Review and Network Meta-analysis [J].
Bundy, Joshua D. ;
Li, Changwei ;
Stuchlik, Patrick ;
Bu, Xiaoqing ;
Kelly, Tanika N. ;
Mills, Katherine T. ;
He, Hua ;
Chen, Jing ;
Whelton, Paul K. ;
He, Jiang .
JAMA CARDIOLOGY, 2017, 2 (07) :775-781
[7]   Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association [J].
Carey, Robert M. ;
Calhoun, David A. ;
Bakris, George L. ;
Brook, Robert D. ;
Daugherty, Stacie L. ;
Dennison-Himmelfarb, Cheryl R. ;
Egan, Brent M. ;
Flack, John M. ;
Gidding, Samuel S. ;
Judd, Eric ;
Lackland, Daniel T. ;
Laffer, Cheryl L. ;
Newton-Cheh, Christopher ;
Smith, Steven M. ;
Taler, Sandra J. ;
Textor, Stephen C. ;
Turan, Tanya N. ;
White, William B. .
HYPERTENSION, 2018, 72 (05) :E53-E90
[8]   Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality, Cardiovascular Deaths, and Cardiovascular Events in Patients With Diabetes Mellitus AMeta-analysis [J].
Cheng, Jun ;
Zhang, Wen ;
Zhang, Xiaohui ;
Han, Fei ;
Li, Xiayu ;
He, Xuelin ;
Li, Qun ;
Chen, Jianghua .
JAMA INTERNAL MEDICINE, 2014, 174 (05) :773-785
[9]   Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus [J].
Cushman, William C. ;
Evans, Gregory W. ;
Byington, Robert P. ;
Goff, David C., Jr. ;
Grimm, Richard H., Jr. ;
Cutler, Jeffrey A. ;
Simons-Morton, Denise G. ;
Basile, Jan N. ;
Corson, Marshall A. ;
Probstfield, Jeffrey L. ;
Katz, Lois ;
Peterson, Kevin A. ;
Friedewald, William T. ;
Buse, John B. ;
Bigger, J. Thomas ;
Gerstein, Hertzel C. ;
Ismail-Beigi, Faramarz .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (17) :1575-1585
[10]   The Preventable Causes of Death in the United States: Comparative Risk Assessment of Dietary, Lifestyle, and Metabolic Risk Factors [J].
Danaei, Goodarz ;
Ding, Eric L. ;
Mozaffarian, Dariush ;
Taylor, Ben ;
Rehm, Juergen ;
Murray, Christopher J. L. ;
Ezzati, Majid .
PLOS MEDICINE, 2009, 6 (04)